Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. The company currently employs 211 people and has generated $50 million in revenue. Entrada Therapeutics focuses on developing a new class of medicines known as Endosomal Escape Vehicle (EEV™)-therapeutics. These therapeutics are designed to efficiently deliver a variety of active agents into cells, targeting a wide range of organs and tissues. This innovative approach utilizes RNA-, antibody-, and enzyme-based programs to address neuromuscular, ocular, metabolic, and immunological diseases. Entrada's lead oligonucleotide programs are specifically being developed to treat individuals with Duchenne muscular dystrophy who are candidates for exon 44, 45, and 50 skipping. The company has also partnered with another entity on VX-670, a clinical-stage program aimed at treating myotonic dystrophy type 1. For more information about Entrada Therapeutics and its work, please visit www.entradatx.com.